Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362592783> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4362592783 endingPage "3900" @default.
- W4362592783 startingPage "3900" @default.
- W4362592783 abstract "Abstract Breast cancer is the most common form of cancer in women with mortality of about 58% in developing countries. HER2+ breast cancers are treated with trastuzumab in various forms in combination with chemotherapy and has been successful in targeting HER2 overexpression in HER2+ breast cancer and improving survival as a standard first line therapy for more than a decade. However, about 25% of early and 75% of late stage HER2 driven breast cancers are resistant to trastuzumab. For these patients, the clinical outcomes are grim. We report the destabilization of HER2 3‘UTR ARE which degraded oncogene HER2 transcript, protein expression, HER2 dependent kinases and interactome. In vitro, we transfected the engineered destabilizing HER2 constructs into BT474 clone 5 trastuzumab resistant breast cancer and within days, we inhibited cancer cell growth and degraded HER2 transcript and protein. The degradation of HER2 leads to loss of many kinases especially YES1 and WNK1 that are known causes of chemoresistance in HER2 positive trastuzumab resistant breast cancer. In vivo, we administered the destabilizing constructs as naked constructs or as complexed with nanocages to mice bearing tumors of BT474 clone 5 trastuzumab resistant cells. We found that our constructs, both the naked and nanocage-delivered, conferred significant survival (p values: 0.0178 and 0.00492) to about 60% of the exceptionally surviving mice compared to the controls. Taken together, we have developed a new therapy to target trastuzumab resistant HER2+ metastatic breast cancers with increased survival outcomes. Citation Format: Chidiebere U. Awah, Joo Sun Mun, Baris Boylu, Alooka Paragodaarachchi, Chika Ochu, Hiroshi Matsui, Olorunseun O. Ogunwobi. In vivo inhibition of metastatic HER2 positive trastuzumab resistant breast cancer using engineered destabilized 3UTR ARE of HER2 improves survival outcomes. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3900." @default.
- W4362592783 created "2023-04-06" @default.
- W4362592783 creator A5002184408 @default.
- W4362592783 creator A5017359974 @default.
- W4362592783 creator A5022231414 @default.
- W4362592783 creator A5045867002 @default.
- W4362592783 creator A5052458999 @default.
- W4362592783 creator A5053687018 @default.
- W4362592783 creator A5064860580 @default.
- W4362592783 date "2023-04-04" @default.
- W4362592783 modified "2023-09-25" @default.
- W4362592783 title "Abstract 3900: <i>In vivo</i> inhibition of metastatic HER2 positive trastuzumab resistant breast cancer using engineered destabilized 3UTR ARE of HER2 improves survival outcomes" @default.
- W4362592783 doi "https://doi.org/10.1158/1538-7445.am2023-3900" @default.
- W4362592783 hasPublicationYear "2023" @default.
- W4362592783 type Work @default.
- W4362592783 citedByCount "0" @default.
- W4362592783 crossrefType "journal-article" @default.
- W4362592783 hasAuthorship W4362592783A5002184408 @default.
- W4362592783 hasAuthorship W4362592783A5017359974 @default.
- W4362592783 hasAuthorship W4362592783A5022231414 @default.
- W4362592783 hasAuthorship W4362592783A5045867002 @default.
- W4362592783 hasAuthorship W4362592783A5052458999 @default.
- W4362592783 hasAuthorship W4362592783A5053687018 @default.
- W4362592783 hasAuthorship W4362592783A5064860580 @default.
- W4362592783 hasConcept C121608353 @default.
- W4362592783 hasConcept C126322002 @default.
- W4362592783 hasConcept C143998085 @default.
- W4362592783 hasConcept C2775930923 @default.
- W4362592783 hasConcept C2777176818 @default.
- W4362592783 hasConcept C2777329042 @default.
- W4362592783 hasConcept C2779786085 @default.
- W4362592783 hasConcept C502942594 @default.
- W4362592783 hasConcept C530470458 @default.
- W4362592783 hasConcept C54355233 @default.
- W4362592783 hasConcept C552990157 @default.
- W4362592783 hasConcept C71924100 @default.
- W4362592783 hasConcept C81089528 @default.
- W4362592783 hasConcept C86803240 @default.
- W4362592783 hasConceptScore W4362592783C121608353 @default.
- W4362592783 hasConceptScore W4362592783C126322002 @default.
- W4362592783 hasConceptScore W4362592783C143998085 @default.
- W4362592783 hasConceptScore W4362592783C2775930923 @default.
- W4362592783 hasConceptScore W4362592783C2777176818 @default.
- W4362592783 hasConceptScore W4362592783C2777329042 @default.
- W4362592783 hasConceptScore W4362592783C2779786085 @default.
- W4362592783 hasConceptScore W4362592783C502942594 @default.
- W4362592783 hasConceptScore W4362592783C530470458 @default.
- W4362592783 hasConceptScore W4362592783C54355233 @default.
- W4362592783 hasConceptScore W4362592783C552990157 @default.
- W4362592783 hasConceptScore W4362592783C71924100 @default.
- W4362592783 hasConceptScore W4362592783C81089528 @default.
- W4362592783 hasConceptScore W4362592783C86803240 @default.
- W4362592783 hasIssue "7_Supplement" @default.
- W4362592783 hasLocation W43625927831 @default.
- W4362592783 hasOpenAccess W4362592783 @default.
- W4362592783 hasPrimaryLocation W43625927831 @default.
- W4362592783 hasRelatedWork W1991018829 @default.
- W4362592783 hasRelatedWork W2081876561 @default.
- W4362592783 hasRelatedWork W2169144202 @default.
- W4362592783 hasRelatedWork W2338354381 @default.
- W4362592783 hasRelatedWork W2420830960 @default.
- W4362592783 hasRelatedWork W2469700170 @default.
- W4362592783 hasRelatedWork W2760932346 @default.
- W4362592783 hasRelatedWork W2931400096 @default.
- W4362592783 hasRelatedWork W2938276334 @default.
- W4362592783 hasRelatedWork W2944980276 @default.
- W4362592783 hasVolume "83" @default.
- W4362592783 isParatext "false" @default.
- W4362592783 isRetracted "false" @default.
- W4362592783 workType "article" @default.